The Educated Pharmacist: Overcoming Clinical Inertia—An Interactive Case Workshop for Optimizing Insulin Use

This activity was originally presented at the 2025 ASHP Midyear Clinical Meeting & Exhibition.

Program Description

Achieving optimal diabetes management and individualized glycemic goals often requires insulin therapy. Insulin is recommended by clinical guidelines to prevent microvascular and macrovascular complications in people living with type 2 diabetes (T2D) when glycemic levels remain above the recommended target. However, the significant personal and logistical burden of insulin regimens, which demand multiple daily injections, can severely impact a patient's daily life and overall well-being. This challenge frequently contributes to therapeutic and clinical inertia, where necessary treatment adjustments are delayed due to concerns over regimen complexity or patient difficulties. This session is specifically designed for practicing pharmacists to address these challenges by comprehensively reviewing the evolving landscape of insulin care, differentiating the efficacy and safety profiles of existing formulations, and examining the potential impact of emerging insulin formulations as well as other strategies to simplify care and alleviate the burden. Presented in a unique, highly interactive workshop format, this session includes an expert faculty panel that will present a collaborative patient case and focused discussions. Pharmacists will gain the necessary skills to identify patients experiencing adherence challenges to complex regimens, apply best practices in sensitive titration and counseling, and highlight shared decision-making strategies to overcome inertia and step into a stronger, more patient-centric leadership role in diabetes care.

Target Audience: Ambulatory care, community, and health system pharmacists

Type of Activity: Application
Release date: December 19, 2025
Expiration date: December 19, 2026
Learner level: Foundational
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify suboptimal medication use in people with type 2 diabetes (T2D) receiving insulin therapy by evaluating individualized glycemic targets and patient-specific factors
• Use glycemic data to propose guideline-aligned insulin modification plans and facilitate therapy adjustment for a person living with T2D receiving insulin therapy
• Employ motivational interviewing and communication techniques to uncover specific patient-related barriers to insulin use supported by individualized patient action plans

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-419-H01-P. The activity is available for CE credit through December 19, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, has the following relevant financial relationship with an ineligible company to disclose:

Consultant: Proteomics International

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Medtronic, Tandem

Speaker's Bureau: Dexcom, Abbott, Insulet, Ascensia, Cequr, Mannkind, Novo Nordisk, Lilly, Cequr

Sneha B Srivastava, PharmD, BCACP, CDCES, DipACLM, FADCESS, has the following relevant financial relationship with an ineligible company to disclose:

Speaker's Bureau: Xeris Pharmaceuticals

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Jennifer Trujillo, PharmD, BCPS, BC-ADM, CDCES, FCCP and Rupal Mansukhani, PharmD, CTTS, FAPhA

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms